Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 641-655, December 2007

Potential therapies based on antidiabetic peptides

  • Sudhesh Kumar, MD, FRCP (Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 024 765 74665; fax: +44 024 765 74871.

Warwick Medical School, University of Warwick, Clifford Bridge Road, University Hospital, Coventry CV2 2DX, UK

Clinical Sciences Research Institute (UofW Campus), Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK

Since adipose tissue was shown to be more than a storage organ, the many cytokines it produces have been identified, along with their roles in energy homeostasis, appetite, and insulin resistance. Concurrently, numerous gut hormones with a diversity of effects have been discovered. They include, amongst many others, peptide YY, ghrelin and oxyntomodulin. As these peptides have been investigated, the potential for their use as novel anti-obesity and antidiabetic therapies has been realized. In this chapter we describe the actions of four of the peptides that have been proposed as the basis for promising new therapies for diabetes: leptin, adiponectin, obestatin and peptide YY. They each have an effect on appetite and, directly or indirectly, on glucose metabolism. We synthesize available data for these peptides and consider the therapeutic potential of each.

Key words: type-2 diabetes, obesity, leptin, adiponectin, obestatin, peptide YY

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-690X(07)00065-6

doi:10.1016/j.beem.2007.07.006

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 641-655, December 2007